Internationalisation of traditional Chinese medicine
Diapharm will assist Chinese pharmaceutical manufacturer Chengdu Huasun Group (www.huasungrp.com) with registering their sanchi-tongshu capsules in Europe. Zhou Yunjin, president of Chengdu Huasun Group, and Ralf Sibbing, managing director of Diapharm, signed a corresponding cooperation agreement in Chengdu on 30 June 2014. The objective is to achieve EU approval for the medicinal product in several EU countries for the treatment of heart ailments. The product is based on active ingredients used in traditional Chinese medicine (TCM).
“Sanchi-tongshu capsules are also a pilot project for the modernisation and internationalisation of traditional Chinese medicine,” Zhou Menglin, vice director of Sichuan Science and Technology Department, emphasised at the signing. Huasun president Zhou Yunjin said: “With a share of more than 40 per cent, Europe is the largest market for traditional medicine.” The Huasun Group is one of the leading manufacturers of biopharmaceuticals and TCM products in China.
(approx. 1,680 characters)